Medexus Pharmaceuticals Company Description
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States.
The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology.
Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
The company’s products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation.
In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products.
The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018.
Medexus Pharmaceuticals Inc. is based in Toronto, Canada.
| Country | Canada |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 82 |
| CEO | Kenneth d'Entremont |
Contact Details
Address: 10 King Street East Toronto, ON M5C 1C3 Canada | |
| Phone | 877 422 5242 |
| Website | medexus.com |
Stock Details
| Ticker Symbol | MEDXF |
| Exchange | OTCMKTS |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| ISIN Number | CA58410Q2036 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kenneth d'Entremont | Chief Executive Officer |
| Brendon Buschman | Chief Financial Officer |
| Richard Labelle | Chief Operating Officer |
| Tina Byers | Head of Investor Relations |